News

Official statistics from the district show that the prevalence rate of malaria in the general population reduced from 77 ...
Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...
Ms Maria Zaituni, a resident of Namuwongo with a family of five children, says the cost of malaria treatment in their slum ...
Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...
Eight months into Donald Trump’s second presidency of the United States, truth and science are again under attack – with ...
Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...
Cash Position: GeoVax reported cash balances of $3,093,862 at June 30, 2025, as compared to $5,506,941 at December 31, 2024. During July 2025, the Company completed a public offering of common stock ...
Key Points - GAAP revenue reached $0.85 million in Q2 2025, exceeding analyst estimates and Revenue more than doubled compared to Q2 2024, also exceeding analyst estimates. GAAP loss per share ...
In Nigeria, malaria is still a critical health concern—one of the leading causes of death. Every year, thousands, especially ...
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...
An estimated 14.3 million children globally remain unvaccinated and vulnerable to vaccine-preventable illnesses – meaning that those children have received no vaccines at all, according to a new ...